



**HAL**  
open science

## **Eco-evolutionary perspectives of the dynamic relationships linking senescence and cancer**

Jean-François Lemaître Lemaître, Samuel Pavard, Mathieu Giraudeau, Orsolya Vincze, Geordie Jennings, Rodrigo Hamede, Beata Ujvari, Frédéric Thomas

► **To cite this version:**

Jean-François Lemaître Lemaître, Samuel Pavard, Mathieu Giraudeau, Orsolya Vincze, Geordie Jennings, et al.. Eco-evolutionary perspectives of the dynamic relationships linking senescence and cancer. *Functional Ecology*, 2020, 34 (1), pp.141-152. 10.1111/1365-2435.13394 . mnhn-02442711

**HAL Id: mnhn-02442711**

**<https://mnhn.hal.science/mnhn-02442711>**

Submitted on 19 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Eco-evolutionary perspectives of the**  
2 **dynamic relationships linking senescence**  
3 **and cancer**

4

5 Lemaître, JF<sup>1</sup>., Pavard, S<sup>2</sup>., Giraudeau, M<sup>3</sup>., Vincze, O<sup>4,5</sup>,  
6 Jennings<sup>6,7</sup>, G., Hamede, R<sup>6,7</sup>, Ujvari, B<sup>6</sup>. & Thomas, F<sup>3</sup>.

7

8 <sup>1</sup> Université de Lyon, F-69000, Lyon; Université Lyon 1; CNRS, UMR5558, Laboratoire de  
9 Biométrie et Biologie Évolutive, F-69622, Villeurbanne, France

10 <sup>2</sup> UMR 7206 EcoAnthropologie et Ethnobiologie, MNHN, Université Paris Diderot, F-75016,  
11 Paris France

12 <sup>3</sup> CREEC, MIVEGEC, UMR IRD/CNRS/UM 5290, 34394 Montpellier, France

13 <sup>4</sup> Hungarian Department of Biology and Ecology, Evolutionary Ecology Group, Babeş-Bolyai  
14 University, Cluj- Napoca, Romania

15 <sup>5</sup>Department of Tisza Research, MTA Centre for Ecological Research, Debrecen, Hungary

16 <sup>6</sup>Centre for Integrative Ecology, School of Life and Environmental Sciences, Deakin  
17 University, Waurn Ponds, Australia

18 <sup>7</sup> School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania  
19 7001, Australia.

20

21

22 **Word count (without references): 6580**

23 **Number of figures: 1**

24 **Number of boxes: 2**

25

26

27

28

29 **Keywords:** aging; carcinogenesis; life-history; immunosenescence; oncobiota; trade-off;

30 tumor

31

32

34 **Abstract**

- 35 1. Evidence for actuarial senescence (i.e. the decrease in survival with increasing age) are  
36 now widespread across the tree of life. However, demographic senescence patterns are  
37 highly variable both between and within species. To understand these variations, there is  
38 an urgent need to go beyond aggregated mortality rates and to investigate how age-specific  
39 causes of mortality in animals interact with age-specific physiological performance. We  
40 address this question in the context of cancers.
- 41 2. Cancer is a leading cause of death in human populations and has recently been shown to be  
42 more prevalent across species than previously thought. Since anthropogenic perturbations  
43 drastically increase cancer rates in wild populations of animals, deciphering the complex  
44 interactions between senescence and cancer now constitute a key challenge in evolutionary  
45 ecology.
- 46 3. Based on classical evolutionary theories of aging, we first demonstrate that the occurrence  
47 of cancers might constitute an underestimated piece of the life-history jigsaw. We propose  
48 that the selection for an increased allocation of resources towards growth and reproduction  
49 during early-life might potentially favor cancer development, a life-history pathway that  
50 might be functionally mediated by the process of immunosenescence. While we discuss the  
51 relevance of other proximate mechanisms suggesting that cancer arises as a direct  
52 consequence of senescence, we also argue that cancer itself can promote senescence by  
53 notably increasing the amount of resources required for somatic maintenance.
- 54 4. Contrary to theoretical predictions, recent empirical evidence suggests that senescence is an  
55 asynchronous process among physiological functions. At the same time, the timing of  
56 occurrence varies widely between the different types of cancers. We suggest that similar  
57 evolutionary forces might shape the synchronicity of senescence and cancer patterns,  
58 which emphasize the tight and complex relationships linking these processes.
- 59 5. We propose a conceptual background to lay down the foundations and the directions of  
60 future research projects aiming to disentangle the dynamic relationship between the  
61 evolution of cancer and senescence. We argue that studies embracing these research  
62 directions will markedly improve our understanding of both cancer prevalence and timing  
63 at the individual, population and species level.

## 67 **1. THE PROBLEMATICS OF SENESCENCE AND CANCER**

68

69 The last decades have seen a burst in the number of studies providing evidence for a decrease  
70 in survival and reproductive success with increasing age (processes coined actuarial and  
71 reproductive senescence, respectively) in both wild and captive populations of animals (Jones  
72 et al., 2014; Nussey, Froy, Lemaître, Gaillard, & Austad, 2013). Such declines in age-specific  
73 life history traits are supposed to be underlined by a progressive deterioration of organism  
74 along the life course (henceforth coined ‘senescence’), generally described in free-ranging  
75 populations through a loss of body mass (e.g. Douhard, Gaillard, Pellerin, Jacob, & Lemaître,  
76 2017) or physiological performance (e.g. immune performance, Ujvari & Madsen, 2011).  
77 While the demographic senescence process appears pervasive across species, the complex  
78 interplay between the deterioration of physiological functions and body condition and the  
79 concomitant increase in susceptibility to diseases culminating in death, is yet to be  
80 deciphered. The ‘emperor of all maladies’, cancer, illustrates this complexity.

81 Cancer is a leading cause of death worldwide in humans (Bray et al., 2018) and, albeit  
82 the extensive investment into molecular and cellular research focusing on the mechanisms of  
83 carcinogenesis, whether senescence and cancer development share similar evolutionary  
84 pathways remains to be determined (De Magalhães, 2013). Currently, the lack of congruence  
85 between mechanistic and eco-evolutionary models linking age-specific deterioration of  
86 physiological functions and cancer hinders our understanding of the role of cancer in actuarial  
87 and reproductive senescence. In addition, the limited information available on cancer  
88 incidence in relation to age in wild populations (Albuquerque, Drummond do Val, Doherty, &  
89 de Magalhães, 2018; Madsen et al., 2017) hinders any empirical assessment of the functional  
90 relationship linking demographic senescence and carcinogenesis. While cancer is ubiquitous  
91 in multicellular organisms (Aktipis et al., 2015), we are not yet able to predict a species’

92 cancer prevalence with respect to its phylogenetic history, ecology, physiology, lifestyle and  
93 biodemographic strategy (Thomas, Kareva, et al., 2018). In fact, based on limited data, cancer  
94 prevalence and age-specific incidence appear not to lie in any of the known ecological  
95 continua structuring the diversity of life-history strategies (e.g. slow-fast continuum, Gaillard  
96 et al., 2016), nor fitting the dominant mechanistic molecular and cellular model of  
97 carcinogenesis (see Box 1).

98 Cancer originates from the (epi)genetic alterations of a given cell. The dominant  
99 theory (also referred to as the ‘Doll-Armitage multistage model’, Armitage & Doll, 1954) is  
100 that carcinogenesis is a multistage process of accumulation of (epi)mutations in a mitotic cell  
101 lineage that liberates a cell from homeostatic mechanisms of cell division; often due to  
102 inhibited attrition of telomeres. Although it has recently been argued that lifetime risk of  
103 cancer correlates with the total number of cell divisions in a given tissue (Tomasetti, Li, &  
104 Vogelstein, 2017; Tomasetti & Vogelstein, 2015), the kinetics of damage accumulation with  
105 age and its consequences on the age-specific patterns of cancer prevalence and incidence  
106 remain largely unknown (Rozhok & DeGregori, 2015). Furthermore, these proximate factors  
107 of carcinogenesis (i.e. (epi)genetic instability and telomere attrition) also belong to the  
108 ‘primary hallmarks’ of aging by being involved in the progressive deterioration of various  
109 biological functions (López-Otín, Blasco, Partridge, Serrano, & Kroemer, 2013). Variations in  
110 cancer prevalence between and within species should thus be mainly determined by  
111 differential somatic mutation rate and repair efficiency. As the immediate results of the  
112 proximal deteriorations occurring with age, both processes of carcinogenesis and senescence  
113 should be tightly linked. However, understanding the causality of the relationship linking  
114 cancer and senescence (at cellular, individual and population levels) and deciphering their  
115 complexity through the lenses of evolutionary biology is particularly arduous (Hofman et al.,  
116 2019). In that context, several hypotheses have recently emerged. The aim of this article is

117 thus to provide a critical reappraisal of these new hypotheses and to identify salient research  
118 directions that evolutionary ecologists should embrace.

119         Once a cancer cell is generated (even by a multistage process), cancer cell  
120 proliferation is then mediated by both the immune response and the competition between  
121 cancer and normal cell lineages. It has thus been recently argued that cancer incidence and  
122 prevalence are mostly shaped by defense mechanisms preventing tumor cells to transform into  
123 invasive cancer (Harris, Schiffman, & Boddy, 2017). Immunosenescence (i.e. the decline in  
124 immune function with increasing age) can therefore lead to increased cancer incidence due to  
125 decreasing efficiency in cancer cells' predation and increased inflammation with age. In  
126 addition, the senescence process might induce a change in the cells' adaptive landscape  
127 making healthy cells less competitive compared to cancer cells (Liggett & DeGregori, 2017).  
128 If true, mortality and cancer incidence should exhibit a similar pattern with age. However,  
129 while the current prevailing paradigm posits that all physiological functions should senesce at  
130 the same pace (Maynard Smith, 1962; Williams, 1957), recent studies have demonstrated that  
131 this may not be true (Gaillard & Lemaître, 2017), which could potentially explain differences  
132 in the shape of cancer incidence and age-specific mortality by other causes. To evaluate these  
133 different hypotheses, it is mandatory to first determine whether individual-based mechanistic  
134 theory of carcinogenesis can be embedded within a population-based evolutionary theory of  
135 senescence.

136

## 137 **2. DOES CANCER MEDIATE THE REPRODUCTION – SENESCENCE TRADE-** 138 **OFF?**

139 The predominant hypothesis related to the evolution of senescence is based on an  
140 evolutionary trade-off between reproduction and subsequent mortality. This trade-off takes its  
141 origin in the '*antagonistic pleiotropy theory*' of aging (Williams, 1957). Based on the

142 assumption that the force of natural selection against fitness impairing genes decreases with  
143 age (Hamilton, 1966; Medawar, 1952), George C. Williams proposed that allele(s) can be  
144 selected by natural selection through a positive effect on reproductive success during early life  
145 even if such allele(s) is responsible for increased senescence in late life. While detecting such  
146 alleles is challenging, experimental manipulations in laboratory models and quantitative  
147 genetic approaches performed on wild populations of animals have provided support to this  
148 theory (see Gaillard & Lemaître, 2017 for a review). The key role of reproductive allocation  
149 in shaping reproductive and actuarial senescence patterns was then emphasized in the  
150 ‘*disposable soma theory*’ of aging (see Kirkwood, 2017 for a comprehensive review), a  
151 theory originally focusing on the maintenance of molecular and cellular integrity (Kirkwood,  
152 1977). In its current form, the disposable soma theory adopts assumptions and predictions that  
153 are common with life history theory as they both give a pivotal role to the principle of  
154 allocation (Cody, 1966), namely that individuals need to share a finite pool of resources  
155 extracted from the environment between different functions like growth, reproduction and  
156 survival (Kirkwood & Rose, 1991; Stearns, 1992). However, the disposable soma theory  
157 explicitly involves the concept of ‘*somatic maintenance*’ (Holliday, 1995) based on evidence  
158 that organisms have evolved dedicated but costly mechanisms (e.g. enzymatic complexes)  
159 that insure the fidelity of DNA replication and repair, as well as the accuracy of protein  
160 synthesis (Gladyshev, 2016). Therefore, resources devoted to growth and reproduction cannot  
161 be simultaneously used for somatic maintenance, which might compromise cellular integrity  
162 and, on the long-run, be responsible for a premature and/or accelerated reproductive and  
163 actuarial senescence (Kirkwood, 2017; Kirkwood & Rose, 1991).

164 Both the antagonistic pleiotropy and the disposable soma theories of aging (Kirkwood  
165 & Rose, 1991; Williams, 1957) jointly predict a negative relationship between reproductive  
166 effort in early-life and fitness-related traits in late-life. This prediction has been so far broadly

167 validated through the use of genetic and phenotypic data and across a wide range of  
168 organisms (Lemaître et al., 2015). As the occurrence of cancers impairs survival prospects,  
169 whether the development of tumor can be embedded in such early- vs late-life trade-off  
170 deserves some attention (Jacqueline et al., 2017). While this question remains largely open, it  
171 could potentially shed new lights on the genetic and physiological pathways linking  
172 reproductive allocation and age-specific survival probabilities in the elderly.

173         At the genetic level, a few alleles involved in carcinogenesis but conferring  
174 advantages in terms of reproductive success have been identified (i.e. Inherited Cancer  
175 Mutant Alleles, see Arnal et al., 2016 for a review). Among them, the *Xmrk* melanoma-  
176 promoting oncogene found in fish from the genus *Xiphophorus* constitutes an iconic example.  
177 In *Xiphophorus cortezi*, the presence of melanoma on the male caudal fin exacerbates the  
178 spotted caudal melanin pattern, which ultimately increases female preference during mate  
179 choice experiments, even if it shortens the duration of reproductive lifespan (Fernandez &  
180 Morris, 2008). Although this example suggests that cancer might mediate the genetic trade-off  
181 between reproduction and survival predicted by the antagonistic pleiotropy of aging, it is  
182 important to notice that such clear-cut examples remain rare, sometimes equivocal, and  
183 mostly limited to human and laboratory models (e.g. *BRCA1/2* mutations, see Smith, Hanson,  
184 Mineau, & Buys, 2012).

185         In non-model organisms, fine-scale genetic data are generally unavailable and most  
186 supports for early- vs late-life trade-offs rely on covariation patterns between life-history traits  
187 depicting reproductive effort and lifespan and/or senescence measurements (Lemaître et al.,  
188 2015). Interestingly, reproductive effort has also been associated with the risk of developing  
189 cancer in wild populations of animals (Jacqueline et al., 2017). For instance, in Tasmanian  
190 devils (*Sarcophilus harrisii*), female fecundity rates were positively associated with the risk  
191 of contracting facial tumors (the Tasmanian devil facial tumor disease, DFTD, one of the very

192 rare example of transmissible cancer) during their lifetime (Wells et al., 2017), and males that  
193 are the most aggressive during intersexual competition suffer from a stronger risk of  
194 contracting the disease through bites (Hamede, McCallum, & Jones, 2013; Figure 1).  
195 Currently, it is unclear whether a resource allocation trade-off *per se* mitigates the relationship  
196 between reproductive expenditure and cancer occurrence observed in Tasmanian devils.  
197 Indeed, under a ‘disposable soma’ framework, individuals that direct resources towards  
198 growth and reproduction might compromise the allocation of resources to costly DNA repair  
199 mechanisms (e.g. Vilchez, Saez, & Dillin, 2014), which can increase DNA damages and  
200 ultimately open the door for the development of cancer (Freitas & de Magalhães, 2011, Figure  
201 1). Although the relative importance of facial tumor occurrence in terms of actuarial and  
202 reproductive senescence (e.g. Russell et al., 2018) have not yet been quantified, the stronger  
203 decline in body condition in affected male Tasmanian devils compared to affected females  
204 suggests that this cancer influences sex differences in lifespan and actuarial senescence  
205 patterns (Ruiz-Aravena et al., 2018).

206 A higher risk of carcinogenesis when the level of intraspecific competition is high has  
207 been theoretically investigated by Boddy and colleagues (2015) in a model where  
208 competitiveness is a declining function of allocation into cancer defenses. This model predicts  
209 that cancer should be more prevalent in males than in females (as observed in humans, see  
210 Clocchiatti, Cora, Zhang, & Dotto, 2016). As the increased cell proliferation associated with  
211 the rapid growth of body size or secondary sexual traits can also increase cancer susceptibility  
212 (De Magalhães, 2013), males who grow faster and also develop and maintain conspicuous  
213 sexual traits might be at higher risk of cancers, especially malignancies of the reproductive  
214 system (e.g. testes cancer, antleromas). This also suggests that, in such species, cancer might  
215 potentially trigger male reproductive senescence rather than actuarial senescence, and  
216 potentially contributes to the observed uncoupling between these two processes (Gaillard &

217 Lemaître, 2017). Taken together, these predictions from theoretical approaches combined  
218 with evidence that both reproductive allocation and cancer defense mechanisms are  
219 energetically costly, strongly highlight that the development of some cancers might be seen as  
220 a long-term reproductive cost (Boddy, Kokko, Breden, Wilkinson, & Aktipis, 2015). The  
221 picture might be even more complex, at least in females, where an absence or a very low rate  
222 of reproduction might itself increase the risk of developing cancers of the reproductive system  
223 (Pesavento, Agnew, Keel, & Woolard, 2018). Basically, females that do not reproduce will  
224 experience a higher number of oestrous cycles and thus a greater exposure to oestrogen,  
225 which can ultimately lead to higher risk of cancers, as observed in humans (Britt & Short,  
226 2012) and captive mammals (Pesavento et al., 2018).

227         Although the fine-scale quantifications of cancer prevalence in the wild remains  
228 challenging (Madsen et al., 2017), theoretical predictions and the availability of long-term  
229 physiological and demographic data on free-ranging populations now provide parts of the  
230 necessary material for studying the relationship between both reproductive and actuarial  
231 senescence and cancer in the light of early- and late-life trade-offs. In addition, such datasets  
232 should also open up opportunities to investigate in depth the genetic and physiological bases  
233 of these processes. In the next section, we argue that among the physiological mechanisms  
234 underlying these relationships immunosenescence might play a critical role.

235

### 236 **3. DOES CANCER RESULTS FROM IMMUNOSENESCENCE?**

237 Immunosenescence involves the progressive morpho-functional involution of organs, as well  
238 as an age-related deterioration of cellular and humoral immune functions (Malaguarnera et al.,  
239 2001). The atrophy of the thymus (the key organ for T-cell maturation) leads to decreased  
240 number of lymphoid precursor T-cells and to the impairment of T-cell proliferative capacity  
241 with increasing age (see Malaguarnera et al., 2001 for a review). By acting as antibody-

242 specific antigen presenting cells, T-cells provide support to the development of antibody  
243 responses by B-cells (i.e. T cell-dependent B cell activation (Parker, 1993)). CD4+ T cells  
244 provide helper signal to B cells to initiate their proliferation (Kurosaki, Kometani, & Ise,  
245 2015), and the lack of T cells can result in minimal memory B cell development (Lafrenz &  
246 Feldbush, 1981). Therefore reduced functioning of T-cells can limit the production of specific  
247 high-affinity antibodies potentially leading to a more restricted antibody repertoire (Rubelt et  
248 al., 2012; van Dijk-Hård, Söderström, Feld, Holmberg, & Lundkvist, 1997). In parallel, with  
249 advancing age, the number of naïve lymphocytes and early progenitor B-cells in the bone  
250 marrow also decrease, and the rate of B-cell maturation and generation decline (Allman &  
251 Miller, 2005; Linton & Dorshkind, 2004). The decreased productions of T and B immune  
252 cells ultimately limit the efficiency of the adaptive immune system to cope with pathogens  
253 (Weksler, 2000). In addition, while the efficiency of the humoral immune system's also  
254 generally declines with increasing age (Ujvari & Madsen, 2011; Weksler, 2000), other arms  
255 of the immune system follow different age-specific trajectories. For example, the number of  
256 other key innate immune cells may actually increase with age or remain constant over the  
257 lifecourse (e.g. Cheynel et al., 2017 in two wild populations of roe deer, *Capreolus*  
258 *capreolus*). Overall, immunosenescence has now been documented in a wide range of species  
259 (e.g. Garschall & Flatt, 2018; Ujvari & Madsen, 2011) and is believed to strongly impair  
260 reproductive and survival prospects at late ages.

261         Because malignant cells are immunogenic, the immune system has the potential to  
262 recognize and to suppress carcinogenesis. In other words, the immune system not only plays a  
263 crucial role in recognizing, controlling and eliminating foreign pathogens, but also has the  
264 ability to recognize and remove malignant cells (Muenst *et al.* 2016). Therefore, age  
265 associated waning of immunity has been proposed to contribute to increased cancer incidence  
266 in older individuals (Pawelec 2017; see Figure 1 and Box 2 for further details on the

267 mechanistic pathways involved). Moreover, the persistent antigenic stimulation caused by  
268 infection with pathogens (e.g. Cytomegalovirus) throughout the lifetime of an organism may  
269 also generate an inflammatory environment favorable for tumor growth, and also concurrently  
270 to direct resources from tumor surveillance to elimination of pathogens (Fulop et al., 2013;  
271 Mancuso et al., 2018; Box 2). The dysfunction of immunity as the organism grows older will  
272 thus impair their ability to respond to diverse challenges, such as parasites and malignant  
273 cells.

274         The functional relationships linking immunosenescence and cancer emphasize that  
275 life-history and evolutionary theories of aging can illuminate our understanding of  
276 carcinogenesis. Indeed, between-individual variation in immunosenescence patterns (and thus  
277 in cancer resistance) can thus be explained by differential allocation of resources towards  
278 costly biological functions such as growth or reproduction, in line with predictions of the  
279 disposable soma theory of aging (Figure 1). There is now a tremendous amount of evidence  
280 that maintaining baseline immunity or mounting an immune response is energetically costly  
281 (Lochmiller & Deerenberg, 2000) and might be impaired by increased allocation to growth or  
282 reproduction, as evidenced by experimental manipulations of brood size in birds (Demas,  
283 Greives, Chester, & French, 2012; Knowles, Nakagawa, & Sheldon, 2009). For instance,  
284 experimental increase in brood size in collared flycatcher (*Ficedula albicollis*) reduced their  
285 level of antibody response against Newcastle disease virus (Nordling, Andersson, Zohari, &  
286 Lars, 1998). A decrease in immunocompetence following reproductive allocation has also  
287 been observed in European rabbits (*Oryctolagus cuniculus*) where both neutrophils and  
288 lymphocytes counts were lower in females that allocated heavily to reproduction (Rödel,  
289 Zapka, Stefanski, & Holst, 2016). Moreover, several phylogenetic comparative studies have  
290 highlighted that immunocompetence is superior in species exhibiting slow pace-of-life (Pap et  
291 al., 2015; Tella, Scheuerlein, & Ricklefs, 2002) indicating that an efficient immune system is

292 a key to a long life. Further studies, that investigate the association between life history  
293 strategies and immunosenescence, not only from the classical host-parasite spectrum, but also  
294 by considering malignant cells (i.e. the oncobiota) as selective force (Russell *et al.* 2018;  
295 Thomas *et al.* 2018), are thus urgently needed.

296

#### 297 **4. FROM MOSAIC AGING TO ASYNCHRONICITY OF AGE-SPECIFIC CANCER** 298 **INCIDENCE**

299 Predictions from early evolutionary studies suggest that senescence should be a highly  
300 synchronized process among phenotypic traits or biological functions (Maynard Smith, 1962;  
301 Williams, 1957). However, increasing amount of evidence show that age-specific patterns of  
302 senescence might be asynchronous between and among physiological and demographic traits  
303 (Gaillard & Lemaître, 2017; Hayward *et al.*, 2015). In line with this observation, age- and  
304 site- specific cancer incidences are exemplary of such asynchronicity.

305         Despite extensive research over the last 50 years, it remains unclear why certain  
306 tissues are significantly more vulnerable than others to developing or hosting malignancies.  
307 While Tomasetti and Vogelstein (2015) suggested that two-thirds of cancer types can be  
308 explained by tissue-specific stem-cell division rates, Wu and colleagues (2016) rather  
309 proposed that cancer risk is heavily influenced by environmental factors. More recently,  
310 Thomas and colleagues (2016) suggested an alternative explanation based on the evolutionary  
311 ecology of organs that could explain why some neoplasms develop into lethal tumors while  
312 others remain benign for decades. This approach considers that the ecological conditions that  
313 characterize each organ, along with the way natural selection has optimized organs to  
314 maximize the individual's fitness, contribute to explaining the spatial and temporal patterns of  
315 cancer occurrences in the body. Furthermore, through time, cellular and tissue senescence  
316 may alter differently the various ecological parameters inside the organs as well as the

317 efficiency of their natural defenses against cancer. Mosaic aging (sensu Walker & Herndon,  
318 2010), the heterogenous and idiosyncratic pattern of age on different cells, organs and system,  
319 therefore could also be extended to cancer.

320         In complex multicellular organisms, organs correspond to ecosystems with their own  
321 distinct ecologies (Thomas et al., 2016). For instance, organs are characterized by particular  
322 structures, functions, abiotic (e.g., glucose, oxygen gradients, temperature, pH) and biotic  
323 conditions (microbial community), the extent of carrying capacity and spatial distribution of  
324 resources, the dimensions of networks with other organs, and last but not least, by the expanse  
325 of contact with the external world. Furthermore, organs differ in the way they relate to fitness,  
326 some being more essential than others for keeping the organism alive and reproduce  
327 efficiently (Thomas et al., 2016). For instance, vital organs such as the heart, brain, and  
328 pancreas are essential for survival, while others, such as the gallbladder and spleen, are not. In  
329 addition, organs found in pairs (lungs or kidneys) can still function even if only one is  
330 damaged. The assumption that organs are perfect by design and intended to maximize health  
331 and lifespan is a common misconception in medicine (Brüne & Hochberg, 2013). The  
332 evolutionary perspective (Nesse & Williams, 1996) emphasizes that trade-offs and constraints  
333 limit the perfection of every organ, and that selection maximizes reproductive success at the  
334 expense of health and lifespan. This implies that organs less crucial for survival and  
335 reproduction should be more vulnerable to pathologies (Thomas et al., 2016). Alternatively,  
336 the strong selection for efficient reproduction that operates on reproductive organs, possibly  
337 associated with a higher expression of genes with antagonistic effects (see Section 2), might  
338 explain why, once standardized for organ mass, prostate and ovaries show the highest rates of  
339 cancer incidence in humans (Silva et al., 2011).

340         These concepts are fundamental to understand organ and age-specific incidences and  
341 prevalence of cancer in different organs. Akin to microbes, cancer cells depend on their tissue

342 environment for sustenance and proliferation. The local ecological conditions in organs  
343 should therefore substantially influence cancer dynamics. In accordance with this idea, it is  
344 increasingly recognized that tumor development, progression, and metastasis are strongly  
345 dependent on the microenvironmental conditions experienced by cancer cells (Bissell &  
346 Hines, 2011). Interactions such as competition, mutualism, and antagonism are likely to shape  
347 the somatic evolution of cancer cells (Crespi & Summers, 2005; Marusyk & Polyak, 2010).  
348 Deterioration of organs with age may also favor malignant proliferation. Reduced cell  
349 proliferation and increased cell death with aging display substantial variations among organs,  
350 as illustrated by Richardson and colleagues (2014). These authors showed that the loss of  
351 functional mass in tissues with aging, which is related to the mitotic rate or rates of tissue  
352 turnover, is organ specific. With aging, highly proliferative tissues also exhibit greater  
353 telomere erosion and hence replicative senescence (Ishii et al., 2006). In young persons, tissue  
354 maintenance involves the removal of old and/or damaged cells, followed by their replacement  
355 by stem cells providing progenitors. Conversely, in the elderly, the most proliferative tissues  
356 display a lack of homeostasis and lose functional mass due to mutations of TP53, a  
357 mechanism/process that is also frequently involved in the age-related rise of cancer incidences  
358 (Richardson, Allan, & Le, 2014).

359         The adaptive theory proposed by DeGregori (2018) also provides an interesting  
360 conceptual framework to understand why the general of process of senescence can locally  
361 promote cells carrying malignant mutations and hence cancer. In this theory, tissues and  
362 organs are equivalent to adaptive landscapes, and healthy cells are best adapted to live in  
363 healthy young tissue. However, age-specific decline in tissue and organ structures or  
364 functions alter the adaptive landscapes, so that cells with oncogenic mutations may suddenly  
365 find themselves better adapted to their surroundings and hence may be able to out-compete  
366 healthy cells. Thus, while oncogenic mutations may always be present and/or accumulate

367 through time, it is the state of the tissue environment that becomes the key determinant that  
368 either favors or disfavors cancer development. For instance, introduction of oncogenes into  
369 old bone marrow progenitors in an old bone marrow environment in mice, often leads to  
370 clonal expansion and leukemia. Conversely, this is not observed when oncogenes are  
371 introduced into young bone marrow progenitors in a young bone marrow environment in mice  
372 (Henry et al., 2015). Therefore, the age-related decline in tissues and organs (e.g. Lui et al.,  
373 2019 for a case study on skin senescence) promotes selection for new cellular phenotypes  
374 adapted to the new microenvironment. Interestingly, alteration in cellular niches due to aging  
375 seems to be specific compared to other causes. For instance, lung cancers in the elderly and in  
376 smokers rely on different mutations (on EGFR and KRAS, respectively), while it is not  
377 expected that carcinogens from smoking induce KRAS mutations only (DeGregori, 2018).

378 To conclude, eco-evolutionary approaches offer promising frameworks to investigate  
379 variations in cancer risk between organs and tissues. However, to go further, one would need  
380 to extend the classical evolutionary theory of aging that aggregates all causes of death at the  
381 organism level and predict synchronisation of senescence of physiological functions  
382 (Maynard Smith, 1962; Williams, 1957) to a model which encompasses the potential  
383 asynchronicity of senescence and trade-offs between physiological functions and anatomical  
384 sites.

385

386

## 387 **5. DYNAMIC INTERPLAY AND TRADE-OFF BETWEEN SENESCENCE AND** 388 **CANCER**

389 Because age is the strongest predictor of metastatic cancer development, it is usually assumed  
390 that cancer is a pathology of old ages (Frank, 2004; Rozhok & DeGregori, 2016). This  
391 correlation may indeed involve causal processes, when for instance advancing age  
392 predisposes cells to accumulate oncogenic mutations, alters tissue microenvironments in a

393 way that favors cells carrying oncogenic mutations (Section 4), and /or alter the efficiency of  
394 the mechanisms that normally hold *in situ* tumors in check (Section 3 and Box 2). However  
395 malignant pathologies also display a range of characteristics suggesting that the occurrence of  
396 cancer might not automatically be a consequence of senescence (Thomas, Vavre, et al., 2018).

397         Although the accumulation of numerous oncogenic manifestations, (e.g. precancerous  
398 lesions and *in situ* carcinoma) throughout the life (being therefore highly prevalent before  
399 individuals are old, e.g. Bissell & Hines, 2011) might be seen as a direct expression of  
400 cellular, tissues or organs senescence, it might be only indirectly linked to the decline in  
401 fitness with age. Indeed, assuming that natural defenses against malignant progression are  
402 associated with trade-offs for the host (Jacqueline et al., 2017), one must also admit that  
403 oncogenic processes can be a cause, rather than a consequence of senescence. For instance,  
404 even when a cancer is apparently not invasive, we cannot exclude that it is energetically  
405 costly to keep such a cancer sub-lethal (Vittecoq et al. 2013). Under the current evolutionary  
406 theories of aging, the amount of resources devoted to limit malignant progression should,  
407 everything else being equal, impair somatic maintenance (e.g. the efficiency of the immune  
408 system) and ultimately lead to a much more pronounced reproductive and actuarial  
409 senescence. For instance, Arnal and colleagues (2017) found that females in *Drosophila* flies  
410 harbouring early stages of a gut cancer lay their eggs earlier than healthy females prior to their  
411 concomitantly earlier death (Arnal et al., 2017). Since early ages at first reproduction are  
412 often associated with long-term reproductive and survival costs in animals (Lemaître et al.,  
413 2015), this example suggests that cancer development during early-life might strengthen  
414 demographic senescence. Another illustration of cancer-induced alteration in life-history  
415 strategies involves the Tasmanian devil and their aforementioned transmissible facial tumor  
416 disease. Basically, Tasmanian devil populations have responded to the cancer-induced

417 mortality by transitioning from an iteroparous (multiple reproductive cycles) to a semelparous  
418 (single breeding at one year of age) reproduction (Jones et al., 2008).

419       Using an eco-evolutionary perspective to investigate how different hosts (with  
420 different life-history strategies) manage non-invasive (sub-lethal) malignant cells should help  
421 to understand the dynamic relationship linking cancer and senescence. More generally, it is  
422 important to adopt a novel view of malignant pathologies, and recognize not only  
423 invasive/metastatic cancers as selective force, but rather to consider the entire oncobiota  
424 (Thomas et al., 2017). Oncogenic phenomena, taken in their totality, may indeed influence  
425 various aspects of individual fitness and thus modulate the numerous trade-offs occurring at  
426 the individual level (Stearns, 1992), long before negative impacts on age-specific survival and  
427 reproductive probabilities become apparent (Thomas et al., 2017). Embracing this view will  
428 be particularly relevant to understand how the great majority of cancers occurs late in life  
429 even if common malignancies in youth can still impair fitness on the long-run.

430       Finally, the causal link between oncogenic processes and senescence may also be  
431 mediated by trade-offs resulting from our constitutive defenses against cancer as for instance  
432 trade-off between morbidity by cancers and other senescence-related causes of death. One  
433 possible mechanism mediating such trade-off could stem from the senescent-cell's theory of  
434 aging (Van Deursen, 2014). Senescent cells are stem/progenitor cells that stop replication and  
435 cease participating in tissue functioning, and accumulate in tissues with age. Senescent state is  
436 seen as a mean to divert a cell potentially at risk of carcinogenesis to a 'safe' state where,  
437 avoiding replication, it is not a risk of accumulating further mutations. Hence the genes  
438 controlling for the entrance into the senescent state are mainly tumor suppressor genes.  
439 However this has a cost: increased proportion of senescent cells compromises tissue  
440 renewing, functioning and therefore the organism's survival (Baker et al., 2016). Thus,  
441 molecular and cellular theories predict a physiological trade-off between mortality

442 components (dying from cancer or from other causes) mediated by the proportion of  
443 senescent cells (Finkel, Serrano, & Blasco, 2007). For instance, apart from its well-known  
444 cancer-suppressive function, activation of TP53 also modulates (together with other  
445 alternative molecular pathways) cellular senescence and organismal aging (Rufini, Tucci,  
446 Celardo, & Melino, 2013), leading to reduced tissue renewal and repair, stem cell deletion,  
447 and organismal aging through an antagonistic pleiotropy effect (Campisi, 2003; García-Cao et  
448 al., 2002). Accordingly, mutated mice with a phenotypic effect analogous to the up-regulation  
449 of the TP53 gene have a reduced risk of cancer but in return display earlier onset of tissue  
450 atrophy and shortened lifespan (Donehower, 2002; Tyner et al., 2002).

451         Over evolutionary time, selection might also have favored compensatory adaptations,  
452 as illustrated by elephants (*Loxodonta africana*) that are long lived mammals with a high  
453 number of copies of the TP53 gene coding p53 proteins (Abegglen et al., 2015). Although the  
454 relatively low number of vertebrates at the same position as elephants along the slow-fast life  
455 history trait continuum makes it difficult to draw general conclusions, slow species (e.g. long-  
456 lived birds) generally show limited functional and actuarial senescence (Jones et al., 2008).  
457 These examples clearly suggest that focusing on non-classical model organisms offer exciting  
458 opportunities to decipher the intimate relationship linking senescence and cancer, from the  
459 molecular to the whole-organism level. Overall, further studies are needed to determine the  
460 extent to which inter-individual variability in the vulnerability to carcinogenesis (due to  
461 strictly intrinsic or environmentally-driven factors) correlates with differential senescence  
462 rates.

463

## 464 **6. CONCLUSIONS**

465 Our perspective article highlights that the study of the relationship between senescence and  
466 cancer is still at its infancy. More specifically, we emphasize that the current evolutionary

467 theories proposed to explain the evolution of senescence provide a solid background to better  
468 understand both cancer prevalence (e.g. if strong allocation to growth and reproduction  
469 facilitate cancer development) and timing (e.g. if the asynchrony in senescence patterns  
470 parallels the age-specific patterns of cancer development across organs). At the same time, we  
471 demonstrate that cancer might itself promote senescence or can even be embedded in a trade-  
472 off with senescence. Whether the directionality of the relationship between senescence and  
473 cancer varies among individuals, populations or species is currently unknown. However, we  
474 argue that research programs aiming to embrace this question are particularly timely since  
475 modifications of the environmental conditions (especially significant perturbations caused by  
476 human activities) have been associated with increased cancer rates in wild populations.  
477 Although we are currently only scratching the surface of the potential importance of  
478 oncobiota in wild populations living in human-impacted habitats (Giraudeau, Sepp, Ujvari,  
479 Ewald, & Thomas, 2018; Hochberg & Noble, 2017; Pesavento et al., 2018; Vittecoq et al.,  
480 2018), cancer in wildlife has also been suggested to be associated with other anthropogenic  
481 activities, such as nocturnal light pollution, intentional or accidental wildlife feeding, or  
482 reduction of genetic diversity in human-impacted habitats (Giraudeau et al., 2018; Sepp,  
483 Ujvari, Ewald, Thomas, & Giraudeau, 2019). Since both cancer prevalence and demographic  
484 senescence patterns can be modulated by environmental conditions (e.g. Garrott, Eberhardt,  
485 Otton, White, & Chaffee, 2002; Tidière et al., 2016), possibly through the trade-off between  
486 reproduction and somatic maintenance (Lemaître et al., 2015), a greater understanding of the  
487 dynamic interplay between senescence and cancer will become a major question for diverse  
488 research areas such as population dynamics, conservation biology, epidemiology or public  
489 health.

490

491 **ACKNOWLEDGEMENTS**

492 We are grateful to Joao Pedro de Magalhães and one anonymous referee for their constructive  
493 comments on this manuscript. JFL is supported by a grant from the Agence Nationale de la  
494 Recherche (ANR-15-CE32-0002-01) and performed within the framework of the LABEX  
495 ECOFECT (ANR-11-LABX-0048) of Université de Lyon, within the program  
496 “Investissements d’Avenir” (ANR-11-IDEX-0007) operated by the French National Research  
497 Agency (ANR). SP is supported by a grant from the the LabEx BCDiv (ANR-10-LABX-  
498 0003), within the program ‘Investissements d’Avenir’ (ANR-11-IDEX-0004-02). OV is  
499 supported by the Romanian Ministry of Research and Innovation (PN-III-P4-ID-PCE-2016-  
500 0404). BU, RH and FT are also supported by an ARC Linkage (LP170101105), Deakin  
501 SEBE\_RGS\_2019, an ANR TRANSCAN (ANR-18-CE35-0009) and a CNRS “International  
502 Associated Laboratory Grant”.

503

#### 504 **AUTHORS’ CONTRIBUTION**

505 All co-authors conceived the research ideas and contributed to the writing of the manuscript.

506

#### 507 **REFERENCES**

508

- 509 Abegglen, L. M., Caulin, A. F., Chan, A., Lee, K., Robinson, R., Campbell, M. S., ...  
510 Schiffman, J. D. (2015). Potential Mechanisms for Cancer Resistance in Elephants and  
511 Comparative Cellular Response to DNA Damage in Humans. *JAMA*, 314(17), 1850–60.
- 512 Aktipis, C. A., Boddy, A. M., Jansen, G., Hibner, U., Hochberg, M. E., Maley, C. C., &  
513 Wilkinson, G. S. (2015). Cancer across the tree of life: cooperation and cheating in  
514 multicellularity. *Philosophical Transactions of the Royal Society B: Biological Sciences*,  
515 370(1673), 20140219.
- 516 Albuquerque, T. A., Drummond do Val, L., Doherty, A., & de Magalhães, J. P. (2018). From  
517 humans to hydra: patterns of cancer across the tree of life. *Biological Reviews*, 93(3), 1715–  
518 1734.
- 519 Allman, D., & Miller, J. P. (2005). The aging of early B-cell precursors. *Immunological*  
520 *Reviews*, 205(1), 18–29.
- 521 Amulic, B., Cazalet, C., Hayes, G. L., Metzler, K. D., & Zychlinsky, A. (2012). Neutrophil  
522 function: from mechanisms to disease. *Annual Review of Immunology*, 30, 459–489.
- 523 Anisimov, V. N., Ukraintseva, S. V., & Yashin, A. I. (2005). Cancer in rodents: does it tell us  
524 about cancer in humans? *Nature Reviews Cancer*, 5(10), 807.

525 Armitage, P., & Doll, R. (1954). The age distribution of cancer and a multi-stage theory of  
526 carcinogenesis. *British Journal of Cancer*, 8(1), 1.

527 Arnal, A., Jacqueline, C., Ujvari, B., Leger, L., Moreno, C., Faugere, D., ... Renaud, F. (2017).  
528 Cancer brings forward oviposition in the fly *Drosophila melanogaster*. *Ecology and*  
529 *Evolution*, 7(1), 272–276.

530 Arnal, A., Tissot, T., Ujvari, B., Nunney, L., Solary, E., Laplane, L., ... Renaud, F. (2016). The  
531 guardians of inherited oncogenic vulnerabilities. *Evolution*, 70(1), 1–6.

532 Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., ... Pezeshki, A.  
533 (2016). Naturally occurring p16 Ink4a-positive cells shorten healthy lifespan. *Nature*,  
534 530(7589), 184.

535 Bissell, M. J., & Hines, W. C. (2011). Why don't we get more cancer? A proposed role of the  
536 microenvironment in restraining cancer progression. *Nature Medicine*, 17(3), 320.

537 Boddy, A. M., Kokko, H., Breden, F., Wilkinson, G. S., & Aktipis, C. A. (2015). Cancer  
538 susceptibility and reproductive trade-offs: a model of the evolution of cancer defences.  
539 *Philosophical Transactions of the Royal Society B: Biological Sciences*, 370(1673),  
540 20140220.

541 Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global  
542 cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36  
543 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424.

544 Britt, K., & Short, R. (2012). The plight of nuns: hazards of nulliparity. *The Lancet*, 379(9834),  
545 2322–2323.

546 Brüne, M., & Hochberg, Z. (2013). Evolutionary medicine—the quest for a better understanding  
547 of health, disease and prevention. *BMC Medicine*, 11,116.

548 Campisi, J. (2003). Cancer and ageing: rival demons? *Nature Reviews Cancer*, 3(5), 339.

549 Caulin, A. F., Graham, T. A., Wang, L.-S., & Maley, C. C. (2015). Solutions to Peto's paradox  
550 revealed by mathematical modelling and cross-species cancer gene analysis. *Philosophical*  
551 *Transactions of the Royal Society B: Biological Sciences*, 370(1673), 20140222.

552 Cheynel, L., Lemaître, J.-F., Gaillard, J.-M., Rey, B., Bourgoïn, G., Ferté, H., ... Jacob, L.  
553 (2017). Immunosenescence patterns differ between populations but not between sexes in a  
554 long-lived mammal. *Scientific Reports*, 7(1), 13700.

555 Clocchiatti, A., Cora, E., Zhang, Y., & Dotto, G. P. (2016). Sexual dimorphism in cancer.  
556 *Nature Reviews Cancer*, 16(5), 330.

557 Cody, M. L. (1966). A general theory of clutch size. *Evolution*, 20(2), 174–184.

558 Crespi, B., & Summers, K. (2005). Evolutionary biology of cancer. *Trends in Ecology &*  
559 *Evolution*, 20(10), 545–552.

560 De Magalhães, J. P. (2013). How ageing processes influence cancer. *Nature Reviews Cancer*,  
561 13(5), 357.

562 DeGregori, J. (2018). *Adaptive Oncogenesis: A New Understanding of How Cancer Evolves*  
563 *inside Us*. Cambridge, Massachusetts: Harvard University Press.

564 Demas, G., Greives, T., Chester, E., & French, S. (2012). The energetics of immunity:  
565 mechanisms mediating trade-offs in ecoimmunology. In *Ecoimmunology* (Edited by G.  
566 Demas & R.J. Nelson). Oxford University Press.

567 Donehower, L. A. (2002). Does p53 affect organismal aging? *Journal of Cellular Physiology*,  
568 192(1), 23–33.

569 Douhard, F., Gaillard, J.-M., Pellerin, M., Jacob, L., & Lemaître, J.-F. (2017). The cost of  
570 growing large: costs of post-weaning growth on body mass senescence in a wild mammal.  
571 *Oikos*, 126(9), 1329–1338.

572 Fernandez, A. A., & Morris, M. R. (2008). Mate choice for more melanin as a mechanism to  
573 maintain a functional oncogene. *Proceedings of the National Academy of Sciences*, 105(36),  
574 13503–13507.

575 Finkel, T., Serrano, M., & Blasco, M. A. (2007). The common biology of cancer and ageing.  
576 *Nature*, 448(7155), 767.

577 Fleming, J. M., Creevy, K. E., & Promislow, D. E. L. (2011). Mortality in North American  
578 dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death.  
579 *Journal of Veterinary Internal Medicine*, 25(2), 187–198.

580 Frank, S. A. (2004). Age-specific acceleration of cancer. *Current Biology*, 14(3), 242–246.

581 Freitas, A.A., & de Magalhães, J.P. (2011). A review and appraisal of the DNA damage theory  
582 of ageing. *Mutation Research*, 728, 12–22.

583 Fulop, T., Larbi, A., Witkowski, J. M., Kotb, R., Hirokawa, K., & Pawelec, G. (2013).  
584 Immunosenescence and cancer. *Critical Reviews in Oncogenesis*, 18(6).

585 Gaillard, J.-M., & Lemaître, J.-F. (2017). The Williams' legacy: A critical reappraisal of his  
586 nine predictions about the evolution of senescence. *Evolution*, 71(12), 2768–2785.

587 Gaillard, J.-M., Lemaître, J.-F., Berger, V., Bonenfant, C., Devillard, S., Douhard, M., ...  
588 Lebreton, J.-D. (2016). Life Histories, Axes of Variation in. In *Encyclopedia of Evolutionary*  
589 *Biology* (Elsevier, pp. 312–323). Elsevier.

590 García-Cao, I., García-Cao, M., Martín-Caballero, J., Criado, L. M., Klatt, P., Flores, J. M., ...  
591 Serrano, M. (2002). 'Super p53' mice exhibit enhanced DNA damage response, are tumor  
592 resistant and age normally. *The EMBO Journal*, 21(22), 6225–6235.

593 Garrott, R. A., Eberhardt, L. L., Otton, J. K., White, P. J., & Chaffee, M. A. (2002). A  
594 geochemical trophic cascade in Yellowstone's geothermal environments. *Ecosystems*, 5(7),  
595 0659–0666.

596 Garschall, K., & Flatt, T. (2018). The interplay between immunity and aging in *Drosophila*.  
597 *F1000Research*, 7.

598 Giraudeau, M., Sepp, T., Ujvari, B., Ewald, P. W., & Thomas, F. (2018). Human activities  
599 might influence oncogenic processes in wild animal populations. *Nature Ecology &*  
600 *Evolution*, 2, 1065–1070.

601 Gladyshev, V. N. (2016). Aging: progressive decline in fitness due to the rising deleteriome  
602 adjusted by genetic, environmental, and stochastic processes. *Aging Cell*, 15(4), 594–602.

603 Gregory, A. D., & Houghton, A. M. (2011). Tumor-associated neutrophils: new targets for  
604 cancer therapy. *Cancer Research*, 71(7), 2411–2416.

605 Hamede, R. K., McCallum, H., & Jones, M. (2013). Biting injuries and transmission of  
606 Tasmanian devil facial tumour disease. *Journal of Animal Ecology*, 82(1), 182–190.

607 Hamilton, W. D. (1966). The moulding of senescence by natural selection. *Journal of*  
608 *Theoretical Biology*, 12(1), 12–45.

609 Harris, V. K., Schiffman, J. D., & Boddy, A. M. (2017). Evolution of cancer defense  
610 mechanisms across species. In *Ecology and evolution of cancer* (Edited by B. Ujvari, B.  
611 Roche & F. Thomas) Elsevier (pp. 99–110).

612 Hayward, A. D., Moorad, J., Regan, C. E., Berenos, C., Pilkington, J. G., Pemberton, J. M., &  
613 Nussey, D. H. (2015). Asynchrony of senescence among phenotypic traits in a wild mammal  
614 population. *Experimental Gerontology*, 71, 56–68.

615 Henry, C. J., Casás-Selves, M., Kim, J., Zaberezhnyy, V., Aghili, L., Daniel, A. E., ...  
616 Clambey, E. T. (2015). Aging-associated inflammation promotes selection for adaptive  
617 oncogenic events in B cell progenitors. *The Journal of Clinical Investigation*, 125(12), 4666–  
618 4680.

619 Hochberg, M. E., & Noble, R. J. (2017). A framework for how environment contributes to  
620 cancer risk. *Ecology Letters*, 20(2), 117–134.

621 Hoeijmakers, J. H. (2009). DNA damage, aging, and cancer. *New England Journal of Medicine*,  
622 361(15), 1475–1485.

623 Hofman, P., Ayache, N., Barbry, P., Barlaud, M., Bel, A., Blancou, P., ... Demory, M. (2019).  
624 The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back  
625 Again. *Cancers*, 11(2), 250.

626 Holliday, R. (1995). *Understanding ageing*. Cambridge University Press.

627 Ishii, A., Nakamura, K.-I., Kishimoto, H., Honma, N., Aida, J., Sawabe, M., ... Kato, M.  
628 (2006). Telomere shortening with aging in the human pancreas. *Experimental Gerontology*,  
629 41(9), 882–886.

630 Jacqueline, C., Biro, P. A., Beckmann, C., Moller, A. P., Renaud, F., Sorci, G., ... Thomas, F.  
631 (2017). Cancer: A disease at the crossroads of trade-offs. *Evolutionary Applications*, 10(3),  
632 215–225.

633 Jones, M. E., Cockburn, A., Hamede, R., Hawkins, C., Hesterman, H., Lachish, S., ...  
634 Pemberton, D. (2008). Life-history change in disease-ravaged Tasmanian devil populations.  
635 *Proceedings of the National Academy of Sciences*, 105(29), 10023–10027.

636 Jones, O. R., Gaillard, J.-M., Tuljapurkar, S., Alho, J. S., Armitage, K. B., Becker, P. H., ...  
637 Charpentier, M. (2008). Senescence rates are determined by ranking on the fast–slow life-  
638 history continuum. *Ecology Letters*, 11(7), 664–673.

639 Jones, O. R., Scheuerlein, A., Salguero-Gómez, R., Camarda, C. G., Schaible, R., Casper, B. B.,  
640 ... Menges, E. S. (2014). Diversity of ageing across the tree of life. *Nature*, 505(7482), 169.

641 Keane, M., Semeiks, J., Webb, A.E., Li, Y., Quesada, V., Craig, T., ... De Magalhães, J. P.  
642 (2015). Insights into the evolution of longevity from the bowhead whale genome. *Cell*  
643 *Reports*, 10, 112-122.

644 Kirkwood, T. B. (1977). Evolution of ageing. *Nature*, 270(5635), 301.

645 Kirkwood, T. B. (2017). The Disposable Soma Theory. In *The evolution of senescence in the*  
646 *tree of life* (Edited by R. Shefferson, O. R. Jones & R. Salguero-Gomez). Cambridge  
647 University Press.

648 Kirkwood, T. B., & Rose, M. R. (1991). Evolution of senescence: late survival sacrificed for  
649 reproduction. *Philosophical Transactions of the Royal Society B: Biological Sciences*,  
650 332(1262), 15–24.

651 Knowles, S. C., Nakagawa, S., & Sheldon, B. C. (2009). Elevated reproductive effort increases  
652 blood parasitaemia and decreases immune function in birds: a meta-regression approach.  
653 *Functional Ecology*, 23(2), 405–415.

654 Kurosaki, T., Kometani, K., & Ise, W. (2015). Memory B cells. *Nature Reviews Immunology*,  
655 15, 149-159.

656 Lafrenz, D. E., & Feldbush, T. L. (1981). Role of T cells in the development of memory B  
657 cells. Quantitative and qualitative analysis. *Immunology*, 44, 177-186.

658 Lemaître, J.-F., Berger, V., Bonenfant, C., Douhard, M., Gamelon, M., Plard, F., & Gaillard, J.-  
659 M. (2015). Early-late life trade-offs and the evolution of ageing in the wild. *Proceedings of*  
660 *the Royal Society B: Biological Sciences*, 282, 20150209.

661 Liggett, L. A., & DeGregori, J. (2017). Changing mutational and adaptive landscapes and the  
662 genesis of cancer. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1867(2), 84–  
663 94.

664 Linton, P. J., & Dorshkind, K. (2004). Age-related changes in lymphocyte development and  
665 function. *Nature Immunology*, 5(2), 133.

666 Liu, Y., & Zeng, G. (2012). Cancer and innate immune system interactions: translational  
667 potentials for cancer immunotherapy. *Journal of Immunotherapy*, 35(4), 299.

668 Liu, N., Matsumura, H., Kato, T., Ichinose, S., Takada, A., Namiki, T., ... Nishimura, E.K.  
669 (2019). Stem cell competition orchestrates skin homeostasis and ageing. *Nature*, 568, 344-  
670 350.

671 Lochmiller, R. L., & Deerenberg, C. (2000). Trade-offs in evolutionary immunology: just what  
672 is the cost of immunity? *Oikos*, 88(1), 87–98.

673 López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The  
674 Hallmarks of Aging. *Cell*, 153(6), 1194–1217.

675 Madsen, T., Arnal, A., Vittecoq, M., Bernex, F., Abadie, J., Labrut, S., ... Beckmann, C.  
676 (2017). Cancer prevalence and etiology in wild and captive animals. In *Ecology and evolution*  
677 of cancer (Edited by B. Ujvari, B. Roche & F. Thomas) Elsevier (pp. 11–46).

678 Malaguarnera, L., Ferlito, L., Imbesi, R. M., Gulizia, G. S., Di Mauro, S., Maugeri, D., ...  
679 Messina, A. (2001). Immunosenescence: a review. *Archives of Gerontology and Geriatrics*,  
680 32(1), 1–14.

681 Mancuso, S., Carlisi, M., Santoro, M., Napolitano, M., Raso, S., & Siragusa, S. (2018).  
682 Immunosenescence and lymphomagenesis. *Immunity & Ageing*, 15(1), 22.

683 Marusyk, A., & Polyak, K. (2010). Tumor heterogeneity: causes and consequences. *Biochimica*  
684 *et Biophysica Acta (BBA)-Reviews on Cancer*, 1805(1), 105–117.

685 Maynard Smith, J. (1962). Review lectures on senescence. I. The causes of ageing. *Proceedings*  
686 of the Royal Society of London Series B, 157, 115–127.

687 Medawar, P. B. (1952). *An unsolved problem of biology*. London, UK: Lewis.

688 Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016). The  
689 immune system and cancer evasion strategies: therapeutic concepts. *Journal of Internal*  
690 *Medicine*, 279(6), 541–562.

691 Nesse, R. M., & Williams, G. C. (1996). *Why We Get Sick: The New Science of Darwinian*  
692 *Medicine* (1 edition). New York: Vintage.

693 Nolen, S. C., Evans, M. A., Fischer, A., Corrada, M. M., Kawas, C. H., & Bota, D. A. (2017).  
694 Cancer—incidence, prevalence and mortality in the oldest-old. A comprehensive review.  
695 *Mechanisms of Ageing and Development*, 164, 113–126.

696 Nordling, D., Andersson, M. ans, Zohari, S., & Lars, G. (1998). Reproductive effort reduces  
697 specific immune response and parasite resistance. *Proceedings of the Royal Society of*  
698 *London B: Biological Sciences*, 265(1403), 1291–1298.

699 Nunney, L., Maley, C. C., Breen, M., Hochberg, M. E., & Schiffman, J. D. (2015). Peto’s  
700 paradox and the promise of comparative oncology. *Philosophical Transactions of the Royal*  
701 *Society B: Biological Sciences*, 370, 20140177.

702 Nussey, D. H., Froy, H., Lemaitre, J.-F., Gaillard, J.-M., & Austad, S. N. (2013). Senescence in  
703 natural populations of animals: widespread evidence and its implications for bio-gerontology.  
704 *Ageing Research Reviews*, 12(1), 214–225.

705 Palucka, K., Banchereau, J., & Mellman, I. (2010). Designing vaccines based on biology of  
706 human dendritic cell subsets. *Immunity*, 33(4), 464–478.

707 Pap, P. L., Vágási, C. I., Vincze, O., Osváth, G., Veres-Szászka, J., & Czirják, G. Á. (2015).  
708 Physiological pace of life: the link between constitutive immunity, developmental period, and  
709 metabolic rate in European birds. *Oecologia*, 177(1), 147–158.

710 Parker, DC. (1993). T cell-dependent B cell activation. *Annual Review of Immunology*, 11,  
711 331–360.

712 Pawelec, G., Derhovanessian, E., & Larbi, A. (2010). Immunosenescence and cancer. *Critical*  
713 *Reviews in Oncology/Hematology*, 75(2), 165–172.

714 Pesavento, P. A., Agnew, D., Keel, M. K., & Woolard, K. D. (2018). Cancer in wildlife:  
715 patterns of emergence. *Nature Reviews Cancer*, 18, 646–661.

716 Peto, R. (1976). Epidemiology, multi-stage models and short-term mutagenicity tests. In H.  
717 Hiatt, J. Watson, & J.A Winsten (Eds.), *Origins of human cancer* (NY: Cold Spring Harbor  
718 Laboratory, pp. 1403–1423). New York.

719 Peto, R., Roe, F. J., Lee, P. N., Levy, L., & Clack, J. (1975). Cancer and ageing in mice and  
720 men. *British Journal of Cancer*, 32(4), 411.

721 Reuschenbach, M., von Knebel Doeberitz, M., & Wentzensen, N. (2009). A systematic review  
722 of humoral immune responses against tumor antigens. *Cancer Immunology, Immunotherapy*,  
723 58(10), 1535.

724 Richardson, R. B., Allan, D. S., & Le, Y. (2014). Greater organ involution in highly  
725 proliferative tissues associated with the early onset and acceleration of ageing in humans.  
726 *Experimental Gerontology*, 55, 80–91.

727 Rödel, H. G., Zapka, M., Stefanski, V., & Holst, D. von. (2016). Reproductive effort alters  
728 immune parameters measured post-partum in European rabbits under semi-natural conditions.  
729 *Functional Ecology*, 30(11), 1800–1809.

730 Rozhok, A. I., & DeGregori, J. (2015). Toward an evolutionary model of cancer: Considering  
731 the mechanisms that govern the fate of somatic mutations. *Proceedings of the National  
732 Academy of Sciences*, 112(29), 8914–8921.

733 Rozhok, A. I., & DeGregori, J. (2016). The evolution of lifespan and age-dependent cancer  
734 risk. *Trends in Cancer*, 2(10), 552–560.

735 Rubelt, F., Sievert, V., Knaust, F., Diener, C., Lim, T. S., Skriner, K., ... Konthur, Z. (2012).  
736 Onset of immune senescence defined by unbiased pyrosequencing of human immunoglobulin  
737 mRNA repertoires. *PloS One*, 7(11), e49774.

738 Rufini, A., Tucci, P., Celardo, I., & Melino, G. (2013). Senescence and aging: the critical roles  
739 of p53. *Oncogene*, 32(43), 5129.

740 Ruiz-Aravena, M., Jones, M. E., Carver, S., Estay, S., Espejo, C., Storer, A., & Hamede, R. K.  
741 (2018). Sex bias in ability to cope with cancer: Tasmanian devils and facial tumour disease.  
742 *Proceedings of the Royal Society B*, 285(1891), 20182239.

743 Russell, T., Lisovski, S., Olsson, M., Brown, G., Spindler, R., Lane, A., ... Thomas, F. (2018).  
744 MHC diversity and female age underpin reproductive success in an Australian icon; the  
745 Tasmanian Devil. *Scientific Reports*, 8(1), 4175.

746 Sepp, T., Ujvari, B., Ewald, P. W., Thomas, F., & Giraudeau, M. (2019). Urban environment  
747 and cancer in wildlife: available evidence and future research avenues. *Proceedings of the  
748 Royal Society B*, 286(1894), 20182434.

749 Silva, A.S., Wood, S.H., van Dam, S., Berres, S., McArdle, A., & De Magalhães, J. P. (2011).  
750 Gathering insights on disease etiology from gene expression profiles of healthy tissues.  
751 *Bioinformatics*, 27, 3300-3305.

752 Smith, D. W. (1996). Cancer mortality at very old ages. *Cancer: Interdisciplinary International  
753 Journal of the American Cancer Society*, 77(7), 1367–1372.

754 Smith, K.R., Hanson, H.A., Mineau, G.P. & Buys, S.S (2012) Effects of BRCA1 and BRCA2  
755 mutations on female fertility. *Proceedings of the Royal Society of London. Series B:  
756 Biological Sciences*, 279, 1389-1395.

757 Spurrell, E. L., & Lockley, M. (2014). Adaptive immunity in cancer immunology and  
758 therapeutics. *Ecancermedicalscience*, 8, 441.

759 Stearns, S. C. (1992). *The evolution of life histories*. Oxford University Press.

760 Tella, J., Scheuerlein, A., & Ricklefs, R. E. (2002). Is cell-mediated immunity related to the  
761 evolution of life-history strategies in birds? *Proceedings of the Royal Society of London.  
762 Series B: Biological Sciences*, 269(1495), 1059–1066.

763 Thomas, F., Jacqueline, C., Tissot, T., Henard, M., Blanchet, S., Loot, G., ... Ujvari, B. (2017).  
764 The importance of cancer cells for animal evolutionary ecology. *Nature Ecology & Evolution*,  
765 1(11), 1592–1595. doi:10.1038/s41559-017-0343-z

766 Thomas, F., Kareva, I., Raven, N., Hamede, R., Pujol, P., Roche, B., & Ujvari, B. (2018).  
767 Evolved Dependence in Response to Cancer. *Trends in Ecology & Evolution*, 33(4), 269–276.

768 Thomas, F., Nesse, R. M., Gatenby, R., Gidoin, C., Renaud, F., Roche, B., & Ujvari, B. (2016).  
769 Evolutionary ecology of organs: a missing link in cancer development? *Trends in Cancer*,  
770 2(8), 409–415.

771 Thomas, F., Vavre, F., Tissot, T., Vittecoq, M., Giraudeau, M., Bernex, F., ... Beckmann, C.  
772 (2018). Cancer is not (only) a senescence problem. *Trends in Cancer*, 4(3), 169–172.

773 Tidière, M., Gaillard, J.-M., Berger, V., Müller, D. W. H., Bingaman Lackey, L., Gimenez, O.,  
774 ... Lemaître, J.-F. (2016). Comparative analyses of longevity and senescence reveal variable  
775 survival benefits of living in zoos across mammals. *Scientific Reports*, 6(1).

776 Tomasetti, C., Li, L., & Vogelstein, B. (2017). Stem cell divisions, somatic mutations, cancer  
777 etiology, and cancer prevention. *Science*, 355(6331), 1330–1334.

778 Tomasetti, C., & Vogelstein, B. (2015). Variation in cancer risk among tissues can be explained  
779 by the number of stem cell divisions. *Science*, 347(6217), 78–81.

780 Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., ...  
781 Brayton, C. (2002). p53 mutant mice that display early ageing-associated phenotypes. *Nature*,  
782 415(6867), 45.

783 Ujvari, B., & Madsen, T. (2011). Do natural antibodies compensate for humoral  
784 immunosenescence in tropical pythons? *Functional Ecology*, 25(4), 813–817.

785 Van Deursen, J. M. (2014). The role of senescent cells in ageing. *Nature*, 509(7501), 439.

786 van Dijk-Härd, I., Söderström, I., Feld, S., Holmberg, D., & Lundkvist, I. (1997). Age-related  
787 impaired affinity maturation and differential D-JH gene usage in human VH6-expressing B  
788 lymphocytes from healthy individuals. *European Journal of Immunology*, 27(6), 1381–1386.

789 Vaupel, J. W., & Yashin, A. I. (1999). Cancer rates over age, time and place: insights from  
790 stochastic models of heterogeneous populations. *MPIDR Working Papers*, WP-1999-06  
791 (1999).

792 Vilchez, D., Saez, I., & Dillin, A. (2014). The role of protein clearance mechanisms in  
793 organismal ageing and age-related diseases. *Nature Communications*, 5, 5659.

794 Vittecoq, M., Giraudeau, M., Sepp, T., Marcogliese, D. J., Klaassen, M., Renaud, F., ...  
795 Thomas, F. (2018). Turning natural adaptations to oncogenic factors into an ally in the war  
796 against cancer. *Evolutionary Applications*, 11(6), 836–844.

797 Vittecoq, M., Roche, B., Daoust, S. P., Ducasse, H., Missé, D., Abadie, J., ... Thomas, F.  
798 (2013). Cancer: a missing link in ecosystem functioning? *Trends in Ecology & Evolution*,  
799 28(11), 628–635.

800 Walker, L. C., & Herndon, J. G. (2010). Mosaic aging. *Medical Hypotheses*, 74(6), 1048–1051.

801 Weksler, M. E. (2000). Changes in the B-cell repertoire with age. *Vaccine*, 18(16), 1624–1628.


802 Wells, K., Hamede, R. K., Kerlin, D. H., Storer, A., Hohenlohe, P. A., Jones, M. E., &  
803 McCallum, H. I. (2017). Infection of the fittest: devil facial tumour disease has greatest effect  
804 on individuals with highest reproductive output. *Ecology Letters*, 20(6), 770–778.

805 Williams, G. C. (1957). Pleiotropy, natural selection, and the evolution of senescence.  
806 *Evolution*, 11, 398–411.

807 Wu, S., Powers, S., Zhu, W., & Hannun, Y. A. (2016). Substantial contribution of extrinsic risk  
808 factors to cancer development. *Nature*, 529(7584), 43.

809 Yokoyama, W. M., & Plougastel, B. F. (2003). Immune functions encoded by the natural killer  
810 gene complex. *Nature Reviews Immunology*, 3(4), 304.

811  
812  
813  
814



816  
 817  
 818  
 819  
 820  
 821  
 822  
 823  
 824  
 825  
 826  
 827  
 828  
 829

**Figure 1: The life-history origins of carcinogenesis. An individual's allocation to growth and reproduction can increase cancer risk through multiple pathways. The relationship can sometimes be direct if, for example, higher rates of antagonistic interactions during sexual competition elevate the risk of contracting cancers (as observed in Tasmanian devils). More generally, the functional relationships linking the allocation of resources to growth and reproduction might ensue increased DNA damages that can either directly or indirectly (via higher rate of immunosenescence) augment the risk of carcinogenesis. Taken together, this suggests that cancer risk worsens with chronological age.**

830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869

**Box 1 – The paradox of cancer prevalence and age-specific incidence across the tree of life**

*Peto's paradox*: Multistage carcinogenesis predicts that a species' cancer prevalence should be a function of the number of cell divisions (then of species size) per unit of time (then of lifespan). As first noted by Sir Richard Peto (Peto, Roe, Lee, Levy, & Clack, 1975), this prediction seems not to be supported when comparing mice and humans. Mice are about 1000 times smaller and about 30 times shorter lived than humans but cancer incidence is about the same in the two species. This led Peto to ask whether our stem cells are “a billion or a trillion times more "cancer-proof" than murine stem cells?” and “Why don't we all die of multiple carcinoma at an early age? (Peto, 1976, pp 1413-1414). Scarcity of data and more specifically age-specific data yet prevent to properly test whether Peto's paradox holds across taxa (but see (Abegglen et al., 2015). Indeed, while multistage carcinogenesis theory predicts a positive correlation between cancer prevalence and lifespan, cancer morbidity is by contrast obviously negatively correlated to lifespan, an effect never properly accounted for. So far the best hypothesis that accommodates for both the multistage theory and also solves Peto's paradox is the existence of better cancer suppression in larger species compared to small ones (Abegglen et al., 2015; but see Caulin, Graham, Wang, & Maley, 2015). For instance, bowhead whale (*Balaena mysticetus*) carry specific genes involved in DNA repair and cell-cycle regulation that potentially confer advantages against cancers (Keane et al., 2015), which is in line with repeated evidence that long-lived species show more efficient DNA repair mechanisms (Freitas & de Magalhães, 2011). However, many alternative but so far untested hypotheses have also been proposed (see Nunney, Maley, Breen, Hochberg, & Schiffman, 2015 for a synthesis).

*The paradox of deceleration and decline of cancer incidence with age*. Multistage carcinogenesis indeed predicts that cancer incidence with age should closely match in shape the increase of mortality with age. However, this is not the case in humans: after a phase of increase, the cancer incidence curve decelerates and even declines in very old ages (Smith, 1996). As a consequence, the proportion of death by cancer decreases after age 60-70, making cancer less responsible for actuarial senescence and eventually cancer becomes one of the least prevalent cause of death in centenarians (Nolen et al., 2017). This has long been explained by population biases, as the selective disappearance with age of individuals genetically/environmentally more susceptible to cancer (Vaupel & Yashin, 1999). However, such deceleration has also been observed in domestic dog breeds (Fleming, Creevy, & Promislow, 2011) and homogenic rats under controlled environment (Anisimov, Ukraintseva, & Yashin, 2005), leading researchers to argue that this paradox may have some physiological grounds. Here again, its generality across species need to be assessed.

**Box 2 – An overview of the mechanistic pathway linking immunosenescence and cancer**

The first line of defense against both intrinsic and extrinsic challenges is generated by the innate immune system that is able to recognize pathogen-associated molecular patterns (PAMP) conserved among microbes as well as damage-associated molecular patterns (DAMP) generated by damaged cells and tissues (Muenst et al., 2016). The innate immune system produces a fast and low-cost response that ultimately initiates an adaptive immune response during infection and tissue damage/inflammation (Liu & Zeng, 2012).

The first immune effector cells from the innate response that directly target cancer cells include: natural killer cells (NK), dendritic cells (DC), macrophages, polymorphonuclear leukocytes (PMN, such as neutrophils, eosinophils, and basophils), mast cells, and cytotoxic T lymphocytes (Liu & Zeng, 2012). Direct molecular interactions between innate immune cells and cancer have been demonstrated in numerous studies. For example, NK cells kill non-MHC (Major Histocompatibility Complex) expressing cancer cells by producing cytotoxic proteins (i.e. perforin and granzyme) that initiate the apoptosis of cancer cells. NK cells produce stimulatory receptors (e.g. natural killer group 2D), on their cell surface that attaches to ligands on the cancer cell surface and the binding stimulates NK cells to secrete inflammatory cytokines, and induce the death of cancer cells (Yokoyama & Plougastel, 2003). PMN leukocytes and mast cells interact with antibody coated antigens on tumor cells and induce the release of cytokines and chemo-attractants that will recruit DC and macrophages to the cancer cells (Amulic, Cazalet, Hayes, Metzler, & Zychlinsky, 2012; Anisimov et al., 2005; Gregory & Houghton, 2011). DC and macrophages recognize the so called “eat me” signals on apoptotic cells through specific receptors and eliminate the malignant cells by phagocytizing them (reviewed in Liu & Zeng, 2012).

Natural killer T cells (NKT) and DCs also create a bridge between innate and adaptive immune systems by secreting cytokines and chemokines, and stimulate T – and B – cell responses to cancer cells (Palucka, Banchereau, & Mellman, 2010). Tumor associated antigens (TAAs), originating from the large genetic alterations of tumors, are presented via the MHC on the tumor surface and trigger T-cell responses. Secretion of chemokines and cytokines leads to expansion of T cells, and ultimately the malignant cells are destroyed by either cell-mediated or by indirect antibody complement-mediated cytotoxicity (Spurrell & Lockley, 2014). TAA specific adaptive immune responses can be generated by various subsets of T cells such as CD4+ T cells modulating the efficiency of the immune reaction and CD8+ T cells directly destroying TAA expressing cancer cells (Reuschenbach, von Knebel Doeberitz, & Wentzensen, 2009).

Overall, the involution of thymus with advancing age, the production of naïve immune cells (T cells) ceases, reserves of naïve cells become depleted, and susceptibility not only to previously un-encountered pathogens but also to antigens expressed by newly-arising cancers can increase (Fulop et al., 2013; Pawelec, Derhovanessian, & Larbi, 2010).